trastuzumab biosimilar

Sandoz biosimilar trastuzumab, EirGenix trastuzumab development, CHMP opinion trastuzumab, HER2-positive breast cancer, HER2-positive gastric cancer, EGC002 phase III study, , Sandoz oncology portfolio,

Sandoz gets CHMP nod for biosimilar of Herceptin, a drug for HER2+ breast and gastric cancer

Anika Sharma

Sandoz, a leading global player in generic and biosimilar medications, has received a noteworthy endorsement from the Committee for Medicinal ...